How JEMPERLI works1

Blockade of the PD-1 receptor can restore T cell function2,3

JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody that works by binding to PD-1 to block interactions between PD-1 and PD-L1 or PD-L2. This releases the PD-1 pathway-mediated inhibition of the anti-tumor immune response to kill cancer cells.1*

PD-L1=programmed death ligand 1; PD-L2=programmed death ligand 2.

*In mouse tumor models.

Inhibited T-Cell

Inhibited T cell2,3

  • Cancer cells can increase expression of PD-L1 on their surface, which binds to PD-1 on T cells
  • This reduces the immune system's ability to identify and attack the cancer cells
Activated T cell with JEMPERLI (dostarlimab-gxly) PD-1 Inhibitor

Activated T cell with JEMPERLI1-3

  • JEMPERLI binds to PD-1 receptors on the T cells, blocking PD-L1 or PD-L2 interactions
  • This enables the T cell to identify and attack cancer cells by restoring cytotoxic activity in the T cell

JEMPERLI harnesses the power of the immune system1

Icon: Lightbulb
Icon: JEMPERLI (dostarlimab-gxly) Response Rate

Learn about response with
 JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Trial

Explore the pivotal trial
for JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Safety

Learn about the safety and
tolerability profile of JEMPERLI.